

BEST AVAILABLE COPY

Title: INTERNALLY ADMINISTERED THERAPEUTIC AGENTS FOR CRANIAL NERVE DISEASES COMPRISING MESENCHYMAL CELLS AS AN ACTIVE INGREDIENT (As Amended)
Inventor(s): Osamu HONMOU et al.
DOCKET NO.: 033873-0108

1/56





Title: INTERNALLY ADMINISTERED THERAPEUTIC AGENTS FOR


\*

% (CURED REGION TO INJURY REGION)

3/56


2

FIG. 3




27

4/56




Þ


5/56




6 / 56





>



8/56








 $10^6$ 

107


**CELLS** 


Title: INTERNALLY ADMINISTERED THERAPEUTIC AGENTS FOR CRANIAL NERVE DISEASES COMPRISING MESENCHYMAL CELLS AS AN ACTIVE INGREDIENT (As Amended)
Inventor(s): Osamu HONMOU et al.
DOCKET NO.: 033873-0108


11/56



12/56









F16.


14/56



15/56




16/56




17/56


12 HRS LATER




3 DAYS LATER




7 DAYS LATER



18/56







20/56

FIG. 20


6 HRS AFTER
CEREBRAL INFARCTION,
3 HRS AFTER
TRANSPLANT




24 HRS AFTER
CEREBRAL INFARCTION,
21 HRS AFTER
TRANSPLANT



1 WEEK LATER




2 WEEKS LATER




21/56

## FIG. 21

6 HRS AFTER CEREBRAL INFARCTION, JUST







-3 HRS LATER (n=10) UNTREATED (n=30)

22

F16.



BEST AVAILABLE COPY




24/56

FIG. 24

MSC CELLS

**CONTROL** 


G-CSF DAY 3 S.C.



G-CSF+SCF DAY 7 S.C.


CORD BLOOD

25/56





F16.




26/56

FIG. 26


NF

**GFAP** 



## RT-PCR (NF)

## RT-PCR (GFAP)







FIG. 27



BDNF PRODUCTION (NG/10<sup>5</sup> CELL/48-HRS)

28/56






FIG. 29A




30/56



29B

F1G.

31/56




BEST AVAILABLE COPY

Title: INTERNALLY ADMINISTERED THERAPEUTIC AGENTS FOR CRANIAL NERVE DISEASES COMPRISING MESENCHYMAL CELLS AS AN ACTIVE INGREDIENT (As Amended) Inventor(s): Osamu HONMOU et al. DOCKET NO.: 033873-0108


32/56

## FIG. 31AB



33/56

FIG. 31C





NUMBER OF POSITIVE CELLS

34/56

 $\rightarrow_{j}$ 


FIG. 31D







Title: INTERNALLY ADMINISTERED THERAPEUTIC AGENTS FOR

36/56




37/56







F1G. 35

FIG. 36






40/56




DAYS AFTER

Title: INTERNALLY ADMINISTERED THERAPEUTIC AGENTS FOR CRANIAL NERVE DISEASES COMPRISING MESENCHYMAL CELLS AS AN ACTIVE INGREDIENT (As Amended)
Inventor(s): Osamu HONMOU et al.
DOCKET NO.: 033873-0108



42/56



CYTOKINE PRODUCTION (NG/105 CELLS/48-HRS)

43/56






FIG. 41




45/56



F1G.


46/56



47/56


 $\omega_{\epsilon}$ 

FIG. 44




INFARCTION FOLUME

FIG. 45




49/56


<u>.</u>~








51/56



F1G. 48

 $-i_j$ 


52/56




F1G. 49

53/56

**-**}



54/56



BEST AVAILABLE COPY

Title: INTERNALLY ADMINISTERED THERAPEUTIC AGENTS FOR CRANIAL NERVE DISEASES COMPRISING MESENCHYMAL CELLS AS AN ACTIVE INGREDIENT (As Amended) Inventor(s): Osamu HONMOU et al. DOCKET NO.: 033873-0108

55/56

CONTROL ANG I OPO I ET I N

F1G. 52

<

FIG. 53

